Journal Watch · Frontiers in Immunology · 2026
Long term survival in three pancreatic cancer patients following Whipple's procedure and allogeneic hematopoietic cell transplantation.
Further investigations are warranted to confirm its therapeutic value.ClinicalTrials.gov Identifier: NCT02207985.
TL;DR
Further investigations are warranted to confirm its therapeutic value.ClinicalTrials.gov Identifier: NCT02207985.
Key findings
- Patient 2 experienced severe acute gastrointestinal GVHD and recurrent chronic bronchiolitis obliterans.
- He died of esophageal cancer 19 years after PDAC diagnosis.
- Patient 3 experienced graft rejection and multiple medical complications, including radical surgery for colorectal cancer, yet remains cancer-free 15 years after PDAC diagnosis.<h4>Discussion</h4>In conclusion, HCT may confer anticancer effects in patients with radically resected PDAC.
- Further investigations are warranted to confirm its therapeutic value.ClinicalTrials.gov Identifier: NCT02207985.
What they did
The remaining six patients, who served as controls and did not receive HCT, died of progressive PDAC within one to four years. Additionally, a 60-year-old male with PDAC who underwent partial pancreatectomy and gastrectomy received HCT from a matched unrelated donor.<h4>Results</h4>Patient 1 developed mild acute graft-versus-host disease (GVHD) of the skin, followed by chronic GVHD. He subsequently underwent surgery for oral cancer and remains alive 21 years after the initial PDAC diagnosis, with no evidence of recurrence.
Full abstract (original)
Background: <h4>Introduction</h4>Pancreatic ductal adenocarcinoma (PDAC) is associated with an extremely poor prognosis, with long-term survival being exceedingly rare. Here, we follow-up on three long-term survivors.<h4>Methods</h4>This study initially included eight patients with PDAC who underwent radical resection via Whipple's procedure with no evidence of distant metastases. Two of these patients received allogeneic hematopoietic cell transplantation (HCT) in a previously published trial.
What they did: The remaining six patients, who served as controls and did not receive HCT, died of progressive PDAC within one to four years. Additionally, a 60-year-old male with PDAC who underwent partial pancreatectomy and gastrectomy received HCT from a matched unrelated donor.<h4>Results</h4>Patient 1 developed mild acute graft-versus-host disease (GVHD) of the skin, followed by chronic GVHD. He subsequently underwent surgery for oral cancer and remains alive 21 years after the initial PDAC diagnosis, with no evidence of recurrence.
Results & conclusions: Patient 2 experienced severe acute gastrointestinal GVHD and recurrent chronic bronchiolitis obliterans. He died of esophageal cancer 19 years after PDAC diagnosis. Patient 3 experienced graft rejection and multiple medical complications, including radical surgery for colorectal cancer, yet remains cancer-free 15 years after PDAC diagnosis.<h4>Discussion</h4>In conclusion, HCT may confer anticancer effects in patients with radically resected PDAC. Further investigations are warranted to confirm its therapeutic value.ClinicalTrials.gov Identifier: NCT02207985.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1766025 · PubMed 42416078.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
Further investigations are warranted to confirm its therapeutic value.ClinicalTrials.gov Identifier: NCT02207985.
What type of study is this?
It is a clinical study, published in Frontiers in Immunology in 2026. The remaining six patients, who served as controls and did not receive HCT, died of progressive PDAC within one to four years.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1766025. PubMed ID: 42416078. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/long-term-survival-in-three-pancreatic-cancer-patients-following-whipple-766025/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides